In STEP-1, Wegovy produced about 14.9% average body-weight loss over 68 weeks. That is a trial average; individual results vary widely and depend on staying on treatment.
What Wegovy is approved for
Weight reduction and long-term maintenance in adults with obesity, or with overweight and a weight-related condition, and in children 12 and older with obesity; lowering the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight; and noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
Wegovy weight-loss results
Wegovy produced 14.9% mean body-weight reduction in the STEP-1 pivotal trial at 68 weeks. That figure is a mean: within the same trial some people lost far more and a minority lost little, so read it as the middle of a wide spread rather than a target.
How effective is Wegovy?
Mean body-weight change at 68 weeks in the STEP-1 trial. Source: FDA prescribing information.
Vs placebo
+12.5 pts
Strong active-treatment signal
Vs GLP-1 class ceiling
66% of ceiling
Above-average GLP-1
Individual results vary. Trial participants also received lifestyle counseling. Full disclaimer.
Expected weight-loss curve
Mean body-weight change across 68 weeks on Wegovy from the STEP-1 trial. Curve smoothed from published endpoints; individual results vary significantly.
Trial participants also received lifestyle counseling. Real-world results depend on dose adherence, side-effect tolerance, and lifestyle factors.
Why results vary, what happens after stopping, and how GLP-1 medicines compare with other approaches are covered once for the whole class in GLP-1 weight-loss results. Side effects that make people stop early are on the Wegovy side effects page.
FAQ about Wegovy for weight loss
Is Wegovy FDA-approved for weight loss?
Yes. The label's approved uses: weight reduction and long-term maintenance in adults with obesity, or with overweight and a weight-related condition, and in children 12 and older with obesity; lowering the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight; and noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
For what those numbers look like in practice — the share of people who reached each level, the month-by-month timeline, and what happens when you stop — see Wegovy before and after: what the data shows.
Educational only, not medical advice. Full medical disclaimer.